Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, VU University Medical Center, Van der Boechorststraat 7, 1081 BT, Amsterdam, The Netherlands.
Psychopharmacology (Berl). 2012 Jan;219(2):327-40. doi: 10.1007/s00213-011-2405-2. Epub 2011 Jul 19.
The clinical efficacy of the monoamine and noradrenaline transporter inhibitors methylphenidate and atomoxetine in attention deficit/hyperactivity disorder implicates noradrenergic neurotransmission in modulating inhibitory response control processes. Nonetheless, it is unclear which adrenoceptor subtypes are involved in these effects.
The present study aimed at investigating the effects of adrenoceptor agonists on inhibitory response control as assessed in the rodent 5-choice serial reaction time task, a widely used translational model to measure this executive cognitive function.
Consistent with the previous reported effects of atomoxetine, the noradrenaline transporter inhibitor desipramine improved inhibitory response control, albeit the effect size was smaller compared to that of atomoxetine. Methylphenidate exerted a bimodal effect on inhibitory response control. Interestingly, the preferential β2-adrenoceptor agonist clenbuterol improved inhibitory response control. Moreover, clenbuterol improved visuospatial attention in the task, an effect that was also observed with the preferential β1-adrenoceptor agonist dobutamine. By contrast, although the preferential α1-adrenoceptor and α2-adrenoceptor agonists (phenylephrine and clonidine, respectively) and the non-selective β-adrenoceptor agonist (isoprenaline) were found to alter inhibitory response control, this was probably secondary to the simultaneous increments in response latencies and omissions observed at effective doses.
Taken together, these findings further strengthen the notion of noradrenergic modulation of inhibitory response control and attentional processes and particularly reveal the involvement of β2-adrenoceptors therein.
单胺和去甲肾上腺素转运体抑制剂哌甲酯和托莫西汀在注意缺陷/多动障碍中的临床疗效表明,去甲肾上腺素能神经传递在调节抑制反应控制过程中起作用。然而,哪种肾上腺素受体亚型参与这些作用尚不清楚。
本研究旨在研究肾上腺素受体激动剂对啮齿动物 5 选择连续反应时间任务中抑制反应控制的影响,该任务是一种广泛用于测量这种执行认知功能的转化模型。
与托莫西汀先前报道的作用一致,去甲肾上腺素转运体抑制剂去甲丙咪嗪改善了抑制反应控制,尽管其作用大小与托莫西汀相比要小。哌甲酯对抑制反应控制产生双相作用。有趣的是,选择性β2-肾上腺素受体激动剂克仑特罗改善了抑制反应控制。此外,克仑特罗改善了任务中的视觉空间注意力,这种作用也与选择性β1-肾上腺素受体激动剂多巴酚丁胺观察到的作用一致。相比之下,尽管选择性α1-肾上腺素受体和α2-肾上腺素受体激动剂(苯肾上腺素和可乐定,分别)和非选择性β-肾上腺素受体激动剂(异丙肾上腺素)被发现改变了抑制反应控制,但这可能是由于在有效剂量下观察到的反应潜伏期和遗漏的同时增加所致。
总之,这些发现进一步加强了去甲肾上腺素能调节抑制反应控制和注意力过程的概念,并特别揭示了β2-肾上腺素受体在其中的参与。